期刊文献+

游离和前列腺特异性抗原相互关系及临床应用 被引量:2

The Relativity of Free and Total Prostate Specific Antigen and it's Function in Clinic
下载PDF
导出
摘要 目的 评价总前列腺特异性抗原 (tPSA)、游离前列腺特异性抗原 (fPSA)及百分率 (f/tPSA % )检测前列腺癌 (PCa)的相关性及临床价值。方法 用酶免法测定 35例PCa及 73例良性前列腺增生 (BPH)患者血清tPSA水平 ,4tPSA <10ng/ml患者另测其fPSA ,计算f/tPSA(% )。 结果 血清tPSA <4、4~ 10、>10ng/ml者发现PCa的比例组间相比均有统计学意义。 4~ 10ng/ml组 ,PCa和BPH者f/tPSA(% )分别是 9.1± 4.8、16 .4± 6 .1,差别有显著意义 (P <0 .0 1)。结论 tPSA仍是PCa筛查的有效瘤标 ,tPSA低水平时 ,f/tPSA(% )检测PCa则更为灵敏精确。 Objective To evaluate the total and free prostate specific antigen in detecting prostate cancer.Methods Serum total and free PSA were determined by Abbott IMX assay,f/tPSA(%) was calculated.Of the 108 patients,35 had PCa and 73 BPH.Results There was statistic difference of the incidence of PCa with tPSA<4ng/ml,4~10ng/ml,>10ng/ml.There also was statistic difference of f/tPSA(%) between PCa and BPH when 4<tPSA<10ng/ml.Conclusions T-PSA assay is important means to discover prostate carcinoma.When tPSA<10ng/ml,f/tPSA(%) is more sensitive and accurate.
出处 《苏州大学学报(医学版)》 CAS 2002年第1期57-58,共2页 Suzhou University Journal of Medical Science
关键词 前列腺肿瘤 前列腺癌 前列腺特异性抗原 TPSA FPSA f/tPSA% 相互关系 临床应用 Prostate neoplasm Carcinoma Prostate specific antigen
  • 相关文献

参考文献2

  • 1Chen YT, Luderer AA, Thiel RP, et al. Using proportions of free to total prostage - specific antigen to predict the probability of prostate cancer[J ]. Urology, 1996, 47: 518~524
  • 2Oesterting JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios[J ]. J Urol, 1995, 154:1090 ~ 1095

同被引文献14

  • 1Torring N, Vinter- Jensen L, Pedersen SB, et al. Systemic administration of insulin - like growth factor Ⅰ (IGF - Ⅰ) causes growth of the rat prostate[J]. Urol, 1997, 158(1): 222- 7.
  • 2Holly JM, Gunnell DJ, Davey SG. Growth hormone, IGF- Ⅰand cancer. Less intervention to avoid cancer? More intervention to prevent cancer[J]. Endocrinol, 1999, 162(3): 321- 30.
  • 3Chan JM, Stampfer MJ, Giovannucci E,et al. Plasma insulinlike growth factor- Ⅰ and prostate cancer risk: a prospective study[J]. Science, 1998, 279(5350): 563 - 6.
  • 4Shariat SF, Bergamaschi F, Adler HL, et al. Correlation of preoperative plasma IGF - Ⅰ levels with pathologic parameters and progression in patients undergoing radical prostatectomy [J].Urology, 2000,56(3): 423 - 9.
  • 5Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly[J]. Clin Endocrinol Metab,1998, 83(3): 775 - 9.
  • 6Barinaga M. Study suggests new way to gauge prostate cancer risk[J]. Science, 1998, 279(5350): 475.
  • 7Shariat SF, Bergamaschi F, Adler HL, et al. Correlation of preoperative plasma IGF - Ⅰ levels with pathologic parameters and progression in patients undergoing radical prostatectomy [J].Urology, 2000,56(3): 423 - 9.
  • 8Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly[J]. Clin Endocrinol Metab,1998, 83(3): 775 - 9.
  • 9Barinaga M. Study suggests new way to gauge prostate cancer risk[J]. Science, 1998, 279(5350): 475.
  • 10Torring N, Vinter- Jensen L, Pedersen SB, et al. Systemic administration of insulin - like growth factor Ⅰ (IGF - Ⅰ) causes growth of the rat prostate[J]. Urol, 1997, 158(1): 222- 7.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部